Array comparative genomic hybridisation (aCGH) RGCC
The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer.
Monitoring
We have developed a range of cutting-edge tests designed to help discover, analyse and screen cancer cells at every step of the disease.
Metastat RGCC
Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location.
Oncotrail RGCC
Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer.
Oncotrace RGCC
Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis.
Oncocount RGCC
Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood.
